TICKERNERD
Menu
ADMAADMAHealthcare · Biotechnology

ADMA Stock Forecast: ADMA Biologics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$9.47
+0.64% on the day

The 5 Wall Street analysts covering ADMA Biologics, Inc. hold a median 12-month price target of $17 — +79.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 15 Aug 2026 — in the lower half.

Market cap
$2.1B
Ticker Nerd rank
42 / 100
Median analyst target
$17
Analysts covering
5
Total return, dividends reinvested
1W
−4.3%
1M
+6.8%
YTD
−48.1%
1Y
−44.2%
From 52W high
−53.5%
From 52W low
+24.6%
$8
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ADMA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ADMA Biologics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Value
99
Volatility
70
Growth
46
Issuance
41
Revisions
40
Size
36
Accruals
17
Momentum
5

Quality (99): The business earns solid, repeatable profits on what it owns.

Momentum (5): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ADMA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ADMA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20Oct 25Jan 26Apr 26Jul 26ADMAHigh $21Median $17Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $12Median $17High $21

The green dot is the last close — the median target sits +79.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
15 July 2026MizuhoMaintainsOutperform$20 → $17
7 May 2026Canaccord GenuityMaintainsBuy$21 → $18
7 May 2026Canaccord GenuityMaintainsBuy—
7 May 2026MizuhoMaintainsOutperform$24 → $20
7 May 2026MizuhoMaintainsOutperform—
21 Apr 2026Canaccord GenuityInitiatesBuy—
13 Apr 2026MizuhoMaintainsOutperform—
26 Mar 2026Cantor FitzgeraldDowngradeNeutral—
8 May 2025Raymond JamesMaintainsStrong Buy—
4 Mar 2025Cantor FitzgeraldReiteratesOverweight—
8 Nov 2024HC Wainwright & Co.MaintainsBuy—
8 Nov 2024Raymond JamesMaintainsStrong Buy—
14 Oct 2024HC Wainwright & Co.ReiteratesBuy—
20 Sept 2024Cantor FitzgeraldReiteratesOverweight—
12 Aug 2024HC Wainwright & Co.MaintainsBuy—
9 Aug 2024Cantor FitzgeraldMaintainsOverweight—
9 July 2024Cantor FitzgeraldMaintainsOverweight—
20 June 2024MizuhoMaintainsBuy—
10 May 2024Cantor FitzgeraldMaintainsOverweight—
10 May 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ADMA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ADMA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−4.0%
Analysts raising
0
Analysts cutting
1
Fundamentals

ADMA Biologics, Inc. (ADMA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
13.5×

Cheaper than 51% of US stocks

Price / sales
4.1×

Cheaper than 31% of US stocks

Price / book
5.6×

Cheaper than 20% of US stocks

EV / EBITDA
195.7×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
15.9%

Higher than 64% of US stocks

Earnings growth (YoY)
2.0%

Higher than 38% of US stocks

Gross margin
69.4%

Higher than 82% of US stocks

Operating margin
−123.4%

Higher than 12% of US stocks

Net margin
33.0%

Higher than 91% of US stocks

Returns & dividend
Return on equity
41.9%

Higher than 92% of US stocks

Return on assets
21.8%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ADMA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ADMAADMA Biologics, Inc.$2.1B
42
BHVNBiohaven Ltd.$2.1B
24
OCULOcular Therapeutix, Inc.$2.1B
33
NUVBNuvation Bio, Inc.$2.1B
62
PGENPrecigen, Inc.$2.2B
80
RAPPRapport Therapeutics, Inc.$2.2B
42
AUPHAurinia Pharmaceuticals, Inc.$2.1B
96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ADMA Biologics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ADMA news & analysis

Can Asceniv Help ADMA Stock Combat IG Market Challenges?

Zacks Investment Research · 13 Aug 2026neutral

The Zacks report highlights that ADMA Biologics' Asceniv product is driving company growth through rising adoption and real-world evidence, while its Bivigam product faces competitive pressure that is weighing on its sales.

Why it matters — ADMA watchers would care because the strength of Asceniv versus the competitive pressure on Bivigam determines the company's overall sales trajectory in the IG (immune globulin) market.

ADMA Biologics: The Earnings Reset Still Leaves More Upside

Seeking Alpha · 12 Aug 2026positive

ADMA Biologics faces a lower earnings base after a challenging period, but ASCENIV remains its key growth driver. In Q2, ASCENIV revenue rose 24%, gross margin reached 69%, and receivable collection improved, though long-term targets were reduced. The bull case rests on continued ASCENIV growth from this reset base.

Why it matters — ADMA watchers would care because the Q2 results show ASCENIV growth and margin and receivable improvements that underpin confidence in the company's valuation despite the lowered earnings targets.

Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)

Newsfile Corp · 12 Aug 2026negative

National plaintiffs' law firm Berger Montague PC announced an investigation into potential breaches of fiduciary duty by ADMA Biologics' Board of Directors. The investigation examines whether the company engaged in channel-stuffing to boost revenue growth despite declining demand for its flagship product, ASCENIV.

Why it matters — ADMA watchers would care because the investigation raises governance and potential accounting-integrity concerns over how the company's revenue growth was achieved.

ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA

PRNewsWire · 10 Aug 2026negative

The DJS Law Group has announced a class action lawsuit against ADMA Biologics, Inc., alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. Shareholders who bought ADMA shares during the class period are being encouraged to contact the firm about possible lead plaintiff roles.

Why it matters — ADMA watchers would care because the company is now subject to a securities class action alleging misleading conduct, which raises legal and reputational risk.

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law

PRNewsWire · 10 Aug 2026negative

The law firm Schall, Brown & Schwartz LLP reminded investors of a class action lawsuit filed against ADMA Biologics for alleged violations of U.S. securities laws. Shareholders who purchased ADMA shares during the specified class period are encouraged to contact the firm about possible lead plaintiff appointments.

Why it matters — ADMA faces a securities fraud class action lawsuit, which is a legal and reputational matter that watchdogs will want to follow.

FAQ

Frequently asked questions about ADMA stock

What is the ADMA stock price forecast for 2026-2027?

The 5 Wall Street analysts covering ADMA Biologics, Inc. have a median 12-month price target of $17, with estimates ranging from $12 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ADMA stock a buy right now?

Of the 5 analysts covering ADMA Biologics, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ADMA Biologics, Inc. 42 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ADMA?

As at 15 Aug 2026, ADMA Biologics, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will ADMA stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +79.5% from the last close, and Ticker Nerd's factor model ranks ADMA Biologics, Inc. 42 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ADMA stock forecast for 2030?

No analyst covering ADMA Biologics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $21 over the next 12 months.

How has ADMA stock performed over the past year?

ADMA Biologics, Inc. returned -44.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ADMA Biologics, Inc. do?

Adma Biologics Inc. is a commercial biopharmaceutical company specializing in plasma-derived biologics used to treat patients with immune deficiencies and certain infectious disease risks.

What is the latest news on ADMA?

The most recent item we track (Zacks Investment Research, 13 Aug 2026): "Can Asceniv Help ADMA Stock Combat IG Market Challenges?". The Zacks report highlights that ADMA Biologics' Asceniv product is driving company growth through rising adoption and real-world evidence, while its Bivigam product faces competitive pressure that is weighing on its sales.

Company

About ADMA Biologics, Inc.

Adma Biologics Inc. is a commercial biopharmaceutical company specializing in plasma-derived biologics used to treat patients with immune deficiencies and certain infectious disease risks. The company operates an integrated model that spans plasma collection, manufacturing, and commercialization, enabling control over key steps in the supply chain. Its primary business segments are ADMA BioManufacturing, which produces immunoglobulin and related plasma-based therapies, and Plasma Collection Centers, which secure source plasma for its products. Adma Biologics also sells plasma-derived intermediate fractions generated during its FDA-approved manufacturing processes and provides laboratory contracting services, with capabilities that include contract filling, labeling, and packing for select customers. The company serves healthcare providers and patients primarily in the United States, focusing on therapies for individuals with compromised or deficient immune systems who are at elevated risk for infections. Headquartered in Ramsey, New Jersey, Adma Biologics plays a specialized role in the biotechnology and healthcare sectors by supplying targeted plasma-derived therapeutic options.

CEO Mr. Adam S. Grossman · 640 employees · United States · https://www.admabiologics.com